Combination therapy as first-line treatment for hypertension. Export

@article{citeulike:6084224, abstract = {Systemic hypertension is a long-term risk factor for the development of atherosclerotic vascular disease and when uncontrolled is a short-term trigger of acute vascular events such as acute coronary syndromes and stroke. Thus, rapid reduction in BP is desirable. Patients at high risk for vascular disease, such as those with diabetes mellitus, have aggressive goal BP targets because studies have shown that achieving these targets reduces events. Given the dual goals in high-risk patients of reducing BP quickly and to aggressively low targets, the classic 'step therapy' of one drug titrated at a time to reduce BP is inadequate. Combination therapy with at least two potent medications makes more sense, and manufacturers are now increasing their offerings of single-pill combinations for hypertension. Combination pills are popular with patients and increase compliance with therapy. Many believe that renin-angiotensin aldosterone system (RAAS) blockers are the cornerstone of hypertension treatment in patients at high risk for vascular disease. The newer combination pills include a RAAS blocker and diuretics or a long-acting calcium channel antagonist (CCA). Recent studies have shown that a RAAS blocker plus a dihydropyridine CCA is superior to older diuretic-based combinations for preventing cardiovascular events. These considerations support a new approach to the higher risk hypertensive patient: effective doses of RAAS blocker/CCA combination pills to rapidly lower BP to <130/80 mmHg.}, author = {Crawford, Michael H.}, citeulike-article-id = {6084224}, citeulike-linkout-0 = {http://view.ncbi.nlm.nih.gov/pubmed/19178127}, citeulike-linkout-1 = {http://www.hubmed.org/display.cgi?uids=19178127}, issn = {1175-3277}, journal = {American journal of cardiovascular drugs : drugs, devices, and other interventions}, keywords = {bp, combination}, number = {1}, pages = {1--6}, posted-at = {2009-11-08 14:14:25}, priority = {2}, title = {Combination therapy as first-line treatment for hypertension.}, url = {http://view.ncbi.nlm.nih.gov/pubmed/19178127}, volume = {9}, year = {2009} }

TY - JOUR ID - citeulike:6084224 L3 - citeulike-article-id:6084224 N2 - Systemic hypertension is a long-term risk factor for the development of atherosclerotic vascular disease and when uncontrolled is a short-term trigger of acute vascular events such as acute coronary syndromes and stroke. Thus, rapid reduction in BP is desirable. Patients at high risk for vascular disease, such as those with diabetes mellitus, have aggressive goal BP targets because studies have shown that achieving these targets reduces events. Given the dual goals in high-risk patients of reducing BP quickly and to aggressively low targets, the classic 'step therapy' of one drug titrated at a time to reduce BP is inadequate. Combination therapy with at least two potent medications makes more sense, and manufacturers are now increasing their offerings of single-pill combinations for hypertension. Combination pills are popular with patients and increase compliance with therapy. Many believe that renin-angiotensin aldosterone system (RAAS) blockers are the cornerstone of hypertension treatment in patients at high risk for vascular disease. The newer combination pills include a RAAS blocker and diuretics or a long-acting calcium channel antagonist (CCA). Recent studies have shown that a RAAS blocker plus a dihydropyridine CCA is superior to older diuretic-based combinations for preventing cardiovascular events. These considerations support a new approach to the higher risk hypertensive patient: effective doses of RAAS blocker/CCA combination pills to rapidly lower BP to <130/80 mmHg. IS - 1 JF - American journal of cardiovascular drugs : drugs, devices, and other interventions SN - 1175-3277 EP - 6 TI - Combination therapy as first-line treatment for hypertension. VL - 9 SP - 1 KW - bp KW - combination AU - Crawford, Michael PY - 2009/// UR - http://view.ncbi.nlm.nih.gov/pubmed/19178127 ER -